HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Copley Pharmaceutical

This article was originally published in The Rose Sheet

Executive Summary

Copley Pharmaceutical: Launching its generic minoxidil 2% by mid-June, following FDA's May 23 approval of the company's ANDA, Copley says. The product will be sold as "Minoxidil Topical Solution 2% for Men Hair Regrowth Treatment" in a box depicting a balding head. Retail price is expected to be between $12 and $15 per box of two 60 ml bottles, according to the company. Copley's minoxidil approval trails those of Bausch & Lomb, Teva and Alpharm, which began shipping their private label versions of Pharmacia & Upjohn's OTC Rogaine in early May ("The Rose Sheet" May 6, p. 5)...
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS002868

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel